Advertisement

Invitae Corporation NVTA

Set alert

Price alert · NVTA

All alert types
0.02 +0.02 —

Day range unavailable

52-week range unavailable

Open
—
Prev close
0.00
Mkt cap
5.59M
Vol
0
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
—
High
—
Forward P/E
-0.02
Beta
1.59
Short ratio
7.78
Inst. own
47.39%
Dividend
0.00
Ex-div date
Earnings
Feb 27, 2024
50-d avg
0.49938
200-d avg
0.862695
1y target
0.68

3M chart

Chart tools
Interval

Events in this range
  • Feb 27, 2024Earnings: —; estimate -0.29; surprise —%
Signals (14)
NameDateAgo
MACD: Buy SignalMar 1, 20242 years ago
MACD: Sell SignalFeb 8, 20242 years ago
SMA: BearishFeb 7, 20242 years ago
SMA: BearishFeb 7, 20242 years ago
SMA: BullishFeb 6, 20242 years ago
SMA: BullishFeb 6, 20242 years ago
MACD: Buy SignalFeb 6, 20242 years ago
RSI: OversoldFeb 5, 20242 years ago
RSI: OversoldJan 24, 20242 years ago
SMA: BearishJan 3, 20242 years ago
SMA: BearishJan 3, 20242 years ago
MACD: Sell SignalJan 2, 20242 years ago
SMA: BullishDec 14, 20232 years ago
SMA: BullishDec 13, 20232 years ago

Key statistics

Market cap
5.59M
Enterprise value
1.26B
Trailing P/E
0.00
Forward P/E
-0.02
PEG ratio
0.00
Price / sales
0.01
Price / book
0.00
EPS (TTM)
-5.36
Beta
1.59
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-299.14%
Revenue (TTM)
481.58M
Revenue growth
-9.20%
Free cash flow
-34.70M
Total cash
254.57M
Total debt
1.51B
Return on equity
0.00%
Shares outstanding
286.49M
Short % of float
26.20%
50-day average
0.49938
200-day average
0.862695

Analyst view

Consensus: hold

Hold
Price target (mean) 0.68 +3478.9% upside
Target (low)
0.30
Target (mean)
0.68
Target (high)
1.00
Ratings (0m) 5 4 buy · 1 hold · 0 sell
  • Strong buy1
  • Buy3
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Feb 27, 2024

Expected Feb 27, 2024. Consensus EPS estimate -0.29.

Earnings history

Financials — quick view

All financials
NVTA Revenue — quarterly 121.24M
2019-12-312020-03-312020-06-302020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-302023-09-30
NVTA Net income — quarterly -942.11M
2019-12-312020-03-312020-06-302020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-302023-09-30
NVTA EPS — quarterly -3.42
2019-12-312020-03-312020-06-302020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-302023-09-30

Earnings

NVTA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 27, 2024Dec 1, 2023-0.29———
Nov 8, 2023Sep 1, 2023-0.30———
Aug 8, 2023Jun 1, 2023-0.37———
May 9, 2023Mar 1, 2023-0.41———
Feb 28, 2023Dec 1, 2022-0.55———
Nov 8, 2022Sep 1, 2022-0.59———

Upgrades / downgrades

NVTA analyst upgrades and downgrades
DateFirmActionFromTo
Oct 19, 2023Goldman SachsmainSellSell
Aug 14, 2023Piper SandlermainUnderweightUnderweight
Jul 23, 2023Goldman SachsmainSellSell
Jul 20, 2023Goldman SachsmainSellSell
May 14, 2023Raymond JamesdownMarket PerformUnderperform
May 10, 2023Goldman SachsmainSellSell

About Invitae Corporation

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Country
United States
Website
invitae.com

News

Your note

Sign in to keep a note on NVTA — it syncs with the Stock Master app.

Insider holders

NVTA insider holders
InsiderRelationLatest transactionDateShares held
BRIDA THOMASGeneral CounselStock Award(Grant)Oct 17, 2023933,587
GORJANC CHRISTINE MARIEDirectorStock Award(Grant)Apr 26, 2023111,022
GUIGLEY ROBERT MOfficerStock Award(Grant)Sep 21, 2023850,000
KNIGHT KENNETH D.Chief Executive OfficerSaleMay 15, 20231,671,610
NUSSBAUM ROBERT L.OfficerSaleJun 12, 2023569,345
SCHRANK ANA J.Chief Financial OfficerStock Award(Grant)Oct 1, 2023850,000

Institution ownership

NVTA institution ownership
Holder% heldSharesValueReported
ARK Investment Management, LLC12.34%32,942,60619.94MSep 29, 2023
Blackrock Inc.7.99%21,323,63424.10MJun 29, 2023
Nikko Asset Management Americas, Inc.6.33%16,909,63519.11MJun 29, 2023
Sumitomo Mitsui Trust Holdings, Inc.6.33%16,909,63519.11MJun 29, 2023
Vanguard Group Inc4.93%13,174,43614.89MJun 29, 2023
Baker Brothers Advisors, LLC3.33%8,881,10410.04MJun 29, 2023

Fund ownership

NVTA fund ownership
Holder% heldSharesValueReported
ARK ETF Tr-ARK Innovation ETF7.07%18,882,86711.43MSep 29, 2023
ARK ETF Tr-ARK Genomic Revolution ETF3.39%9,058,6225.48MSep 29, 2023
Vanguard Total Stock Market Index Fund2.79%7,454,4148.42MJun 29, 2023
iShares Russell 2000 ETF2.29%6,106,4915.64MAug 30, 2023
Vanguard Extended Market Index Fund1.18%3,141,2043.55MJun 29, 2023
Fidelity Small Cap Index Fund0.88%2,349,3003.34MJul 30, 2023
Advertisement